Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic
strategy using small molecules to induce ubiquitin-dependent degradation of proteins. It has …

Abstract Structure-based drug design uses three-dimensional geometric information of
macromolecules, such as proteins or nucleic acids, to identify suitable ligands. Geometric …

Glycoconjugates are major constituents of mammalian cells that are formed via covalent
conjugation of carbohydrates to other biomolecules like proteins and lipids and often …

Ferroptosis, a type of regulated cell death driven by iron-dependent phospholipid
peroxidation, has captured much attention in the field of nanomedicine since it was coined in …

Checkpoint immunotherapy holds great potential to treat malignancies via blocking the
immunosuppressive signaling pathways, which however suffers from inefficiency and off …

The intracellular interactions of biomolecules can be maneuvered to redirect signaling,
reprogram the cell cycle, or decrease infectivity using only a few dozen atoms. Such …

Proteolysis targeting chimera (PROTAC) is an emerging protein degradation strategy, which
shows excellent advantages in targeting those so-called “undruggable” proteins. However …

Confining the protein degradation activity of proteolysis-targeting chimera (PROTAC) to
cancer lesions ensures precision treatment. However, it still remains challenging to precisely …

Proteolysis targeting chimera (PROTAC) is an emerging pharmacological modality with
innovated post‐translational protein degradation capabilities. However, off‐target induced …

Carbon–heteroatom bonds, most often amide and ester bonds, are the standard method to
link together two complex fragments because carboxylic acids, amines, and alcohols are …